Viela Bio   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Gaithersburg MD United States (2017)
Status: Acquired by Horizon Therapeutics, LLC (2021)

Organization Overview

First Clinical Trial
2018
NCT03621605
First Marketed Drug
2020
inebilizumab
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Viela Bio | VIELA BIO